Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
Keywords: 
Immunotherapy
Interferon-gamma
PD-1
PD-L1
Lung cancer
Melanoma
Issue Date: 
2018
Publisher: 
SAGE Publications
ISSN: 
1758-8340
Note: 
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Citation: 
Karachaliou, N. (Niki); Gonzalez-Cao, M. (María); Crespo, G. (Guillermo); et al. "Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients". Therapeutic advances in medical oncology. 10, 2018, 1 - 23
Abstract
Background: Programmed death-ligand 1 (PD-L1) may be induced by oncogenic signals or can be upregulated via interferon gamma (IFN-y). We have explored whether the expression of IFNG, the gene encoding IFN-y, is associated with clinical response to the immune checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma patients. The role of inflammation-associated transcription factors STAT3, IKBKE, STAT1 and other associated genes has also been examined.

Files in This Item:
Thumbnail
File
1758834017749748.pdf
Description
Size
1.08 MB
Format
Adobe PDF


Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.